Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

@article{Paavonen2009EfficacyOH,  title={Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women},  author={Jorma Paavonen and Paulo Naud and Jorge Salmer{\'o}n and Cosette M. Wheeler and Song‐nan Chow and Dan L Apter and Henry C Kitchener and Xavier Castellsagué and Julio Cesar Teixeira and S. Rachel Skinner and James A. Hedrick and Unnop Jaisamrarn and Genara Limson and Suzanne Marie Garland and Anne Szarewski and Barbara Romanowski and Fred Y. Aoki and Tino F Schwarz and Willy A. J. Poppe and Francesc X. Bosch and David Jenkins and Karin Hardt and Toufik Zahaf and Dominique Descamps and Frank Struyf and Matti Lehtinen and Gary Dubin},  journal={The Lancet},  year={2009},  volume={374},  pages={301-314},  url={https://api.semanticscholar.org/CorpusID:1331989}}

Figures and Tables from this paper

1,547 Citations

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

It is concluded that vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

The high VE observed in Japanese women, accompanied by a sustained immune response and a clinically acceptable safety profile, support findings of large, international trials.

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV- 6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

Results show that the HPV-16/18 AS04-adjuvanted vaccine reduces HPV- 16/18 infection and associated cervical endpoints in women regardless of age, location, or sexual experience.

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

The HPV-16/18 AS04-adjuvanted vaccine was well tolerated with no increase in reactogenicity with subsequent doses and no reports of vaccine-related SAEs and generally well-tolerated in Korean girls aged 10-14 yr.

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial

It is indicated that women with existing HR-HPV infection at vaccination might still benefit from the AS04- HPV-16/18 vaccine, but this potential benefit needs further demonstration in the future.
...

39 References

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

Analysis of this large database shows the HPV-16/18 AS04-adjuvanted cervical cancer vaccine to have a favorable safety profile in women of all ages.

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

In women positive for HPV DNA, HPV-16/18 vaccination does not accelerate clearance of the virus and should not be used to treat prevalent infections.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for approximately 20% of cervical cancers, and the clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and -18 and are needed to fully ascertain the population-based impact and public health significance of these findings.

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

To determine the long-term vaccine efficacy (VE) of HPV16/18 virus-like-particle (VLP) vaccine against cervical carcinoma in situ (CIS+) and invasive cervical carcinomas, the following three population-based cohorts of adolescent women have been enrolled: (1) women vaccinated with the HPV vaccine; (2) women vaccination with hepatitis A control vaccine; and (3) unvaccinated control women.

Related Papers

Showing 1 through 3 of 0 Related Papers